Executive-in-Residence Scott Fisher Named CEO of CavoGene LifeSciences

Originally appeared on Crain’s Cleveland Business, Feb. 4, 2019

Regenerative medicine expert Scott J. Fisher has been named CEO of CavoGene LifeSciences, a biotech company that has licensed a novel investigational gene therapy for patients with neurodegenerative diseases.

Fisher has previously led drug development and gene therapy clinical research of multiple regenerative therapies at early-stage companies, according to the news release.

CavoGene, which will be headquartered at the Global Center for Health Innovation in Cleveland, has secured the exclusive license to SynCav1, a novel and neuron specific gene therapy, from the University California San Diego and the laboratory of Brian P. Head.

READ FULL STORY HERE